SuperC Long Term Plays

[SuperC]

SRNE .23 52wk hi/low .18 - 1.75 Sorrento Therapeutics July 28th 2011 receives Phase I Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH).

http://www.sorrentotherapeutics.com/newsDetail.php?id=25&cid=0001.0000.0000.0000

This peer-reviewed grant was awarded to support the Company's program to generate and develop antibody therapeutics and vaccines to combat Clostridium difficile (C. difficile or C. diff) infections by disrupting quorum sensing, a bacterial communication process believed to control virulence. The Phase I grant is for $300,000 per year for two years, with the possibility of Phase II funding of $1 million per year for up to an additional 3 years.

C. difficile is the most common cause of hospital-acquired infectious diarrhea (C. difficile-associated diarrhea or CDAD). According to the Centers for Disease Control, the annual incidence of CDAD infections in the United States is approximately 478,000 cases: 165,000 in hospitals, 50,000 post hospital discharge, and 263,000 in nursing homes. With an overall mortality rate of 6-7%, CDAD infections impose an estimated financial burden of over $3.9 billion per year on the U.S. healthcare system. The situation is worsening with the emergence of hypervirulent and multi-drug resistant forms. "It is clear that the NIH remains motivated to fund novel approaches to tackling the serious healthcare burden of C. diff. Together with our NIAID-funded program for the control of S. aureus, the Company is targeting the two most prevalent nosocomial infections in the U.S.," said Henry Ji, Ph.D., Chief Scientific Officer and interim Chief Executive Officer of Sorrento Therapeutics.

About the Sorrento Therapeutics C. diff Program

Sorrento Therapeutics has an exclusive worldwide license to utilize the quorum sensing technology developed at The Scripps Research Institute (TSRI), which is the basis for its anti-infectives programs. The importance of the technology is that it targets specific auto-inducing peptides (AIPs) central to the quorum sensing system of C. difficile. Squelching these AIPs leads to a disruption of bacterial communication ("quorum quenching") and could suppress virulence. The grant application was noted to be a highly innovative approach that could potentially expand the technology platform into additional disease indications.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company leveraging its proprietary turn-key human antibody libraries for the discovery and development of human therapeutic antibody products for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic diseases and infectious diseases. More information is available at www.sorrentotherapeutics.com. Information on the Company's website or any other website does not constitute a part of this press release.

http://www.otcmarkets.com/stock/SRNE/financials
Common stock, $0.0001 par value; 500,000,000 shares authorized and 249,809,635 and 250,801,270 shares issued and outstanding at June 30th.

http://www.sorrentotherapeutics.com/

http://www.sorrentotherapeutics.com/news.php?pageSize=6&cID=&word=

From the Frost & Sullivan Award to the impressive grants this one looks too be ready for a long term play. A clear bottom plus the chance to be part of a start up with proper funding.

Other related sites:
http://www.biospace.com/company_profile.aspx?CompanyId=1008744


Will be fun to track this one over the next year. Remember too these types of plays can run well into the dollars when future discoveries are made and without too us the little guy on the outside.

Take time to DD this one, but it's very reasonable to think these large of grants could meet or exceed funding needs for the next year or two without furthering dilution.

A starter position here....

Again so everyone understands and from their website: Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company.

As my wife stated like MRSA [not the same though], this is a huge problem at Hospitals.

Trade Well but do not trade this one OFTEN....

DD_YOU!!

SuperC